CN105073133B - 抗gdf15抗体 - Google Patents
抗gdf15抗体 Download PDFInfo
- Publication number
- CN105073133B CN105073133B CN201380073317.1A CN201380073317A CN105073133B CN 105073133 B CN105073133 B CN 105073133B CN 201380073317 A CN201380073317 A CN 201380073317A CN 105073133 B CN105073133 B CN 105073133B
- Authority
- CN
- China
- Prior art keywords
- seq
- variable region
- cdr
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006895 Cachexia Diseases 0.000 claims abstract description 139
- 208000016261 weight loss Diseases 0.000 claims abstract description 62
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims abstract description 61
- 230000004580 weight loss Effects 0.000 claims abstract description 61
- 102000046181 human GDF15 Human genes 0.000 claims abstract description 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 381
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 132
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 132
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 127
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 127
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 127
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 127
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 127
- 150000007523 nucleic acids Chemical class 0.000 claims description 119
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 111
- 230000027455 binding Effects 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 66
- 239000003112 inhibitor Substances 0.000 claims description 61
- 210000003205 muscle Anatomy 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 45
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 45
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 44
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 39
- 241000124008 Mammalia Species 0.000 claims description 38
- 239000013604 expression vector Substances 0.000 claims description 36
- 208000001076 sarcopenia Diseases 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 108060003951 Immunoglobulin Proteins 0.000 claims description 26
- 102000018358 immunoglobulin Human genes 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 20
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 17
- 101800001586 Ghrelin Proteins 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 14
- 108010056852 Myostatin Proteins 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 102000004378 Melanocortin Receptors Human genes 0.000 claims description 12
- 108090000950 Melanocortin Receptors Proteins 0.000 claims description 12
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 12
- 108010008364 Melanocortins Proteins 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 208000030507 AIDS Diseases 0.000 claims description 8
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 206010040047 Sepsis Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 8
- 108010023082 activin A Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- 239000002876 beta blocker Substances 0.000 claims description 7
- 229940097320 beta blocking agent Drugs 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 7
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 7
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims description 6
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims description 6
- 210000002216 heart Anatomy 0.000 claims description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 39
- 102000006395 Globulins Human genes 0.000 claims 6
- 108010044091 Globulins Proteins 0.000 claims 6
- 102400000442 Ghrelin-28 Human genes 0.000 claims 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 2
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000002018 overexpression Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 150
- 108090000623 proteins and genes Proteins 0.000 description 143
- 241000699670 Mus sp. Species 0.000 description 122
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 88
- 108091028043 Nucleic acid sequence Proteins 0.000 description 88
- 102220465452 Angiogenin_K64Q_mutation Human genes 0.000 description 79
- 238000011282 treatment Methods 0.000 description 63
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 230000037396 body weight Effects 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 42
- 102220126961 rs369936288 Human genes 0.000 description 37
- 108020001507 fusion proteins Proteins 0.000 description 35
- 102000037865 fusion proteins Human genes 0.000 description 35
- 101001037145 Homo sapiens Immunoglobulin heavy variable 2-5 Proteins 0.000 description 34
- 101001138126 Homo sapiens Immunoglobulin kappa variable 1-16 Proteins 0.000 description 34
- 102100040235 Immunoglobulin heavy variable 2-5 Human genes 0.000 description 34
- 102100020946 Immunoglobulin kappa variable 1-16 Human genes 0.000 description 34
- 241001529936 Murinae Species 0.000 description 32
- 210000002966 serum Anatomy 0.000 description 32
- 102220028518 rs199469669 Human genes 0.000 description 29
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 27
- 101001037151 Homo sapiens Immunoglobulin heavy variable 2-70 Proteins 0.000 description 27
- 102100040233 Immunoglobulin heavy variable 2-70 Human genes 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 27
- 201000008808 Fibrosarcoma Diseases 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 20
- 239000007928 intraperitoneal injection Substances 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 108091005461 Nucleic proteins Proteins 0.000 description 15
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 description 14
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 14
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 description 14
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 14
- 230000002710 gonadal effect Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 13
- 102000000589 Interleukin-1 Human genes 0.000 description 13
- 108010002352 Interleukin-1 Proteins 0.000 description 13
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 13
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 12
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 12
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 12
- 238000010494 dissociation reaction Methods 0.000 description 12
- 230000005593 dissociations Effects 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 238000013414 tumor xenograft model Methods 0.000 description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 description 11
- 210000002027 skeletal muscle Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 206010061598 Immunodeficiency Diseases 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 9
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 101150084115 Hdgf gene Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 206010028289 Muscle atrophy Diseases 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000002865 melanocortin Substances 0.000 description 7
- 201000000585 muscular atrophy Diseases 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 235000001258 Cinchona calisaya Nutrition 0.000 description 6
- 101100392289 Mus musculus Gdf15 gene Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 229960000948 quinine Drugs 0.000 description 6
- 239000012146 running buffer Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 238000002869 basic local alignment search tool Methods 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 108010059616 Activins Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 102100026818 Inhibin beta E chain Human genes 0.000 description 4
- 102000004125 Interleukin-1alpha Human genes 0.000 description 4
- 108010082786 Interleukin-1alpha Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000488 activin Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012575 bio-layer interferometry Methods 0.000 description 4
- 230000001612 cachectic effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003324 growth hormone secretagogue Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- JNGVJMBLXIUVRD-SFHVURJKSA-N (2s)-3-(4-cyanophenoxy)-n-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)OC1=CC=C(C#N)C=C1 JNGVJMBLXIUVRD-SFHVURJKSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102000000393 Ghrelin Receptors Human genes 0.000 description 2
- 108010016122 Ghrelin Receptors Proteins 0.000 description 2
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001138089 Homo sapiens Immunoglobulin kappa variable 1-39 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 102100020910 Immunoglobulin kappa variable 1-39 Human genes 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000043168 TGF-beta family Human genes 0.000 description 2
- 108091085018 TGF-beta family Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- VQPFSIRUEPQQPP-MXBOTTGLSA-N anamorelin Chemical compound C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VQPFSIRUEPQQPP-MXBOTTGLSA-N 0.000 description 2
- 108010052640 anamorelin Proteins 0.000 description 2
- 229950005896 anamorelin Drugs 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960001886 rilonacept Drugs 0.000 description 2
- 108010046141 rilonacept Proteins 0.000 description 2
- 102200053764 rs121918299 Human genes 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- UJGGNFGSHPHGNE-AWEZNQCLSA-N 2-[(2r)-1-ethylsulfonyl-2-hydroxypropan-2-yl]-6-(trifluoromethyl)-1h-indole-5-carbonitrile Chemical compound N#CC1=C(C(F)(F)F)C=C2NC([C@@](C)(O)CS(=O)(=O)CC)=CC2=C1 UJGGNFGSHPHGNE-AWEZNQCLSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GRNHLFULJDXJKR-UHFFFAOYSA-N 3-(2-sulfanylethyl)-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)NC2=C1 GRNHLFULJDXJKR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 1
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 101100392288 Macaca fascicularis GDF15 gene Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229940122534 Melanocortin receptor antagonist Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010030596 agouti-related protein-(83-132) Proteins 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003557 bones of lower extremity Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000010454 developmental mechanism Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229950001115 enobosarm Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
- 229950010248 loretin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229950002549 stamulumab Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745508P | 2012-12-21 | 2012-12-21 | |
| US61/745,508 | 2012-12-21 | ||
| US201361827325P | 2013-05-24 | 2013-05-24 | |
| US61/827,325 | 2013-05-24 | ||
| PCT/US2013/077139 WO2014100689A1 (en) | 2012-12-21 | 2013-12-20 | Anti-gdf15 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105073133A CN105073133A (zh) | 2015-11-18 |
| CN105073133B true CN105073133B (zh) | 2021-04-20 |
Family
ID=50069279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380073317.1A Active CN105073133B (zh) | 2012-12-21 | 2013-12-20 | 抗gdf15抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9175076B2 (enExample) |
| EP (2) | EP3689370A1 (enExample) |
| JP (3) | JP6758832B2 (enExample) |
| KR (1) | KR102208861B1 (enExample) |
| CN (1) | CN105073133B (enExample) |
| AR (1) | AR094271A1 (enExample) |
| AU (1) | AU2013364133B2 (enExample) |
| CA (1) | CA2896076C (enExample) |
| DK (1) | DK2934584T3 (enExample) |
| EA (1) | EA038645B1 (enExample) |
| ES (1) | ES2791183T3 (enExample) |
| MX (1) | MX370720B (enExample) |
| WO (1) | WO2014100689A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| MX343729B (es) | 2011-04-08 | 2016-11-18 | Amgen Inc | Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos. |
| MX2014009129A (es) | 2012-01-26 | 2014-11-21 | Amgen Inc | Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15). |
| EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| EP3590537A1 (en) | 2012-09-26 | 2020-01-08 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| WO2014100689A1 (en) * | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US9828415B2 (en) | 2013-01-30 | 2017-11-28 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| EP3063543B1 (en) * | 2013-10-31 | 2020-03-11 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| WO2015143126A1 (en) | 2014-03-19 | 2015-09-24 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| GB2524553C (en) * | 2014-03-26 | 2017-07-19 | Julius-Maximilians-Universitãt Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| DK3122775T3 (da) | 2014-03-26 | 2020-02-03 | Univ Wuerzburg J Maximilians | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
| GB2524552B (en) * | 2014-03-26 | 2017-07-12 | Julius-Maximilians-Universitãt Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| EP3157952B1 (en) * | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| EP3197493B1 (en) | 2014-09-25 | 2021-03-10 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
| KR20170066515A (ko) * | 2014-09-30 | 2017-06-14 | 우니베르지타이트 겐트 | 관절 질환의 치료 방법 |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| ES2799503T3 (es) | 2014-10-31 | 2020-12-18 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| EP4368641A3 (en) * | 2015-04-23 | 2024-08-14 | HaemaLogiX Ltd. | Kappa myeloma antigen chimeric antigen receptors and uses thereof |
| CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
| GB201512733D0 (en) * | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| AU2016333538B2 (en) | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| BR112018006218A2 (pt) | 2015-10-02 | 2018-10-09 | Univ Wuerzburg J Maximilians | iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15 |
| CN108463247B (zh) * | 2015-10-28 | 2022-04-12 | 耶鲁大学 | 人源化的抗dkk2抗体和其用途 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| WO2017136195A1 (en) * | 2016-02-01 | 2017-08-10 | Eli Lilly And Company | Parathyroid hormone – anti-rankl antibody fusion compounds |
| CN108697795A (zh) * | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| CN109069636A (zh) * | 2016-03-04 | 2018-12-21 | 恩格姆生物制药公司 | 用于调节体重的组合物和方法 |
| JP7021099B2 (ja) | 2016-03-31 | 2022-02-18 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 結合タンパク質及びその使用方法 |
| JP7138567B2 (ja) * | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | 成長分化因子１５に対する抗体およびそれらの使用 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| US11773162B2 (en) * | 2016-08-05 | 2023-10-03 | Allakos, Inc. | Anti-Siglec-7 antibodies for the treatment of cancer |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| CA3045700A1 (en) * | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| CA3070100A1 (en) * | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| EP3737410A4 (en) * | 2018-01-11 | 2022-04-20 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| KR20200140878A (ko) | 2018-04-09 | 2020-12-16 | 암젠 인크 | 성장 분화 인자 15 융합 단백질 |
| US20210340263A1 (en) * | 2018-08-09 | 2021-11-04 | The Wistar Institute | Anti-Follicule Stimulating Hormone Receptor Antibodies |
| KR102715542B1 (ko) * | 2018-08-20 | 2024-10-08 | 화이자 인코포레이티드 | 항-gdf15 항체, 조성물 및 사용 방법 |
| KR102238927B1 (ko) * | 2018-08-30 | 2021-04-12 | 서울대학교산학협력단 | 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도 |
| US20220048995A1 (en) * | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
| CR20210193A (es) | 2018-10-22 | 2021-06-15 | Janssen Pharmaceutica Nv | Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas |
| WO2021066751A1 (en) * | 2019-10-02 | 2021-04-08 | Aslan Pharmaceuticals Pte. Ltd. | Antigen specific binding domains and antibody molecules |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| CN111393526B (zh) * | 2020-03-30 | 2022-04-12 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| EP4163300A4 (en) * | 2020-06-04 | 2024-07-03 | Daegu Gyeongbuk Institute Of Science and Technology | Gfral-antagonistic antibody and use thereof |
| JPWO2022092326A1 (enExample) * | 2020-10-30 | 2022-05-05 | ||
| WO2022189936A1 (en) * | 2021-03-08 | 2022-09-15 | Medimmune, Llc | Antibodies directed against gdf-15 |
| BR112023020152A2 (pt) | 2021-03-31 | 2023-11-14 | Cambridge Entpr Ltd | Inibidores terapêuticos de sinalização gdf15 |
| US20250019427A1 (en) | 2021-08-10 | 2025-01-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| JP2024541933A (ja) | 2021-11-02 | 2024-11-13 | ファイザー・インク | 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法 |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023141815A1 (zh) * | 2022-01-26 | 2023-08-03 | 康源博创生物科技(北京)有限公司 | 抗生长分化因子15的抗体分子及其应用 |
| WO2023217068A1 (zh) | 2022-05-09 | 2023-11-16 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116041497A (zh) * | 2022-12-22 | 2023-05-02 | 杭州贤至生物科技有限公司 | 一种猫杯状病毒（fcv）重组蛋白单克隆抗体及制备方法 |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
| WO2025072516A1 (en) * | 2023-09-27 | 2025-04-03 | Aveo Pharmaceuticals, Inc. | Methods of reducing weight loss using anti-gdf15 antibodies |
| WO2025146488A1 (en) | 2024-01-05 | 2025-07-10 | Catalym Gmbh | Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1994003599A1 (fr) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| AU1103900A (en) | 1998-10-07 | 2000-04-26 | Stryker Corporation | Modified tgf-beta superfamily proteins |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| DE60032355T2 (de) | 1999-05-17 | 2007-04-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh | NEUROPROTEKTIVE EIGENSCHAFTEN VON GDF-15, EINEM VERTRETER DER TGF-ß-SUPERFAMILIE |
| JP4920851B2 (ja) | 2000-04-20 | 2012-04-18 | セイント ヴィンセンツ ホスピタル シドニー リミテッド | マクロファージ抑制サイトカイン−１（ｍｉｃ−１）が関連する検査方法 |
| AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| WO2004041170A2 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1575512A4 (en) | 2002-11-08 | 2007-08-29 | Barnes Jewish Hospital | METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE |
| US20060188889A1 (en) | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| WO2005036608A2 (en) | 2003-10-10 | 2005-04-21 | That Corporation | Low-power integrated-circuit signal processor with wide dynamic range |
| WO2005092383A1 (ja) | 2004-03-26 | 2005-10-06 | Takeda Pharmaceutical Company Limited | 呼吸器疾患の予防・治療剤 |
| ES2555956T3 (es) * | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| CA2534871C (en) | 2006-02-15 | 2015-08-04 | The Ohio State University Research Foundation | Three-gene test to differentiate malignant from benign thyroid nodules |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| CA2660691C (en) | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on gdf-15 |
| EP1884777A1 (en) | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| WO2009021293A1 (en) | 2007-08-16 | 2009-02-19 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| JP2011502106A (ja) | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法 |
| EP2103943A1 (en) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs |
| WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
| GB0902793D0 (en) * | 2009-02-20 | 2009-04-08 | Univ Gent | GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes |
| US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| GB201004739D0 (en) | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| TR201802772T4 (tr) * | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2014100689A1 (en) | 2012-12-21 | 2014-06-26 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP3157952B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
-
2013
- 2013-12-20 WO PCT/US2013/077139 patent/WO2014100689A1/en not_active Ceased
- 2013-12-20 AU AU2013364133A patent/AU2013364133B2/en active Active
- 2013-12-20 CA CA2896076A patent/CA2896076C/en active Active
- 2013-12-20 AR ARP130105017A patent/AR094271A1/es active IP Right Grant
- 2013-12-20 CN CN201380073317.1A patent/CN105073133B/zh active Active
- 2013-12-20 EA EA201591198A patent/EA038645B1/ru unknown
- 2013-12-20 ES ES13827058T patent/ES2791183T3/es active Active
- 2013-12-20 EP EP20156883.9A patent/EP3689370A1/en active Pending
- 2013-12-20 EP EP13827058.2A patent/EP2934584B1/en active Active
- 2013-12-20 MX MX2015007751A patent/MX370720B/es active IP Right Grant
- 2013-12-20 KR KR1020157019881A patent/KR102208861B1/ko active Active
- 2013-12-20 US US14/137,415 patent/US9175076B2/en active Active
- 2013-12-20 JP JP2015549810A patent/JP6758832B2/ja active Active
- 2013-12-20 DK DK13827058.2T patent/DK2934584T3/da active
-
2015
- 2015-09-24 US US14/863,870 patent/US9725505B2/en active Active
-
2017
- 2017-07-20 US US15/655,263 patent/US10597444B2/en active Active
-
2019
- 2019-01-21 JP JP2019007928A patent/JP2019056018A/ja not_active Withdrawn
-
2020
- 2020-03-19 US US16/824,034 patent/US11725047B2/en active Active
-
2021
- 2021-01-25 JP JP2021009528A patent/JP2021061864A/ja not_active Withdrawn
-
2023
- 2023-06-16 US US18/336,713 patent/US12258391B2/en active Active
-
2025
- 2025-02-07 US US19/048,087 patent/US20250277019A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105073133B (zh) | 抗gdf15抗体 | |
| EP2566895B1 (en) | Anti-erbb3 antibodies | |
| JP7575102B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| JP2013529076A (ja) | 抗ｆｇｆｒ２抗体 | |
| JP2011504176A (ja) | マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法 | |
| EP3825330A1 (en) | Anti-cd117 antibodies and methods of use thereof | |
| JP2021508707A (ja) | Ｐｄ−ｌ１に対する抗体及びそのバリアント | |
| US20090246205A1 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| JP2022514786A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| WO2011031657A1 (en) | Use of an anti-il6 antibody to decrease hepcidin in cancer patients | |
| Kou et al. | A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin | |
| HK40028061A (en) | Anti-gdf15 antibodies | |
| TW201716439A (zh) | Ｈｅｒ３抗體 | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| HK1215670B (en) | Anti-gdf15 antibodies | |
| US20230064703A1 (en) | Anti-gitr antibodies and uses thereof | |
| CN114929741A (zh) | 针对lif的抗体及其用途 | |
| CN112203685A (zh) | 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗 | |
| HK1178184B (en) | Anti-erbb3 antibodies | |
| BR112015014768B1 (pt) | Anticorpos anti-gdf15, seu método de produção, seu uso, e composição farmacêutica compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |